[HTML][HTML] The dual PPARα/γ agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats
LC Pickavance, CL Brand, K Wassermann… - British journal of …, 2005 - ncbi.nlm.nih.gov
LC Pickavance, CL Brand, K Wassermann, JPH Wilding
British journal of pharmacology, 2005•ncbi.nlm.nih.govIn 6-and 10-week-old obesity-prone (fa/fa) Zucker diabetic fatty (ZDF) rats, effects of
prevention and intervention therapies, respectively, were compared between PPARα/γ
agonist, ragaglitazar (RAGA) and separate PPARγ and α agonists, pioglitazone (PIO) and
bezafibrate (BF).
prevention and intervention therapies, respectively, were compared between PPARα/γ
agonist, ragaglitazar (RAGA) and separate PPARγ and α agonists, pioglitazone (PIO) and
bezafibrate (BF).
Abstract
1. In 6-and 10-week-old obesity-prone (fa/fa) Zucker diabetic fatty (ZDF) rats, effects of prevention and intervention therapies, respectively, were compared between PPARα/γ agonist, ragaglitazar (RAGA) and separate PPARγ and α agonists, pioglitazone (PIO) and bezafibrate (BF).
ncbi.nlm.nih.gov